Keywords
Cannabidiol
Epilepsy
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the use of cannabidiol in the symptomatic treatment of Lennox-Gastaut Syndrome (LGS) and its adverse effects. Literature review: The use of cannabidiol is efficient in the treatment of LGS, whether at a dose of 10mg/kg/d or 20mg/kg/d, in reducing the frequency of seizures and improving the quality of life of patients and families. A reduction in the frequency of seizures is observed in patients with LGS after the use of cannabidiol, especially when combined with other anticonvulsants, especially at a dosage of 20 mg/kg/day. However, it is also necessary to understand that increasing the dose leads to some adverse effects, such as diarrhea, nausea, drowsiness and an increase in liver transaminases. Final considerations: There is little evidence linking the use of cannabidiol with other anticonvulsants in GLS. From this perspective, the objective of the study was to evaluate the use of cannabidiol in the symptomatic treatment of Lennox-Gastaut Syndrome, so that this therapy is discussed in the sociocultural and scientific context in an imperative manner. SLG – Lennox-Gastaut Syndrome
References
ALALAWI A, et al. Cannabidiol improves vocal learning-dependent recovery from, and reduces magnitude of deficits following, damage to a cortical-like brain region in a songbird pre-clinical animal model. Neuropharmacology, 2019; 158: 107716.
AL-BANJI, M e ZAHR D, et al. Lennox-Gastaut syndrome. Management update. Neurosciences, 2015; 20(3) : 207–212.
ALI S e SCHEFFER IE, et al. Efficacy of cannabinoids in paediatric epilepsy. Developmental Medicine & Child Neurology, 2018; 61(1): 13–18.
ARZIMANOGLOU A, et al. Epilepsy and cannabidiol: a guide to treatment. Epileptic Disorders: International Epilepsy Journal with Videotape [Internet], 2020; 22(1): 1–14.
ASADI-POOYA AA. Lennox-Gastaut syndrome: a comprehensive review. Neurological Sciences, 2017; 39(3): 403–414.
AUVIN S. Lennox-Gastaut syndrome: New treatments and treatments under investigation. Revue Neurologique, 2020; 176(6): 444–447.
CHEN J e BORGELT LM, et al. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes. Annals of Pharmacotherapy [Internet], 2019; 53(6): 603–611.
CRUMRINE PK. Lennox-Gastaut Syndrome. Journal of Child Neurology, 2002; 17(1): 70–75.
DALE T, et al. Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder. Epilepsy Research, 2019; 151: 31–39.
DEVINSKY O, et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. New England Journal of Medicine, 2018; 378(20): 1888–1897.
FRANCO V e BIALER M, et al. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. Neuropharmacology, 2021; 185: 108442.
GASTON TE e SZAFLARSKI JP. Cannabis for the Treatment of Epilepsy: an Update. Current Neurology and Neuroscience Reports, 2018; 18(11).
GONZALEZ-GIRALDO E e SULLIVAN JE. Advances in the Treatment of Drug-Resistant Pediatric Epilepsy. Seminars in Neurology [Internet], 2020; 40(2): 257–262.
GUNNING, B, et al. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta Neurologica Scandinavica [Internet], 2021; 143(2): 154–163.
HUESTIS MA, et al. Cannabidiol adverse effects and toxicity. Current neuropharmacology, 2019; 17(10): 974–989.
KOO CM, et al. Cannabidiol for treating Lennox-Gastaut syndrome and Dravet syndrome in Korea. Journal of Korean medical science, 2020; 35(50): 427.
LATTANZI S, et al. Cannabidiol efficacy and clobazam status: A systematic review and meta‐analysis. Epilepsia, 2020; 61(6): 1090–1098.
LATTANZI S, et al. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox–Gastaut Syndrome: A Systematic Review and Meta-Analysis. CNS Drugs, 2018; 32(10): 905–916.
LATTANZI S, et al. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs, 2018; 78(17): 1791–1804.
LATTANZI S, et al. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs, 78(17): 1791.
LATTANZI S, et al. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome. CNS Drugs, 2021; 35(3): 265–281.
MASTRANGELO M. Lennox–Gastaut Syndrome: A State of the Art Review. Neuropediatrics, 2017; 48(3): 143–151.
NEUBERGER EE e CARLSON JJ, et al. Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome. PharmacoEconomics, 2020; 38(11): 1237–1245.
NUNES ML e GEIB LTC, et al. Incidence of epilepsy and seizure disorders in childhood and association with social determinants: a birth cohort study. Jornal de Pediatria, 2011.
PATSALOS PN, et al. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. Epilepsia, 2020.
PIETRAFUSA N, et al. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy. Paediatric drugs [Internet], 2019. Disponível em: https ://www.ncbi.nlm.nih.gov/pubmed/31179531. Acesso em: 31 maio 2024.
PRIVITERA M, et al. Epilepsia, 2021; 62(5): 1130–1140.
PRIVITERA M, et al. Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials. Epilepsia, 2021; 62(5): 1130–1140.
SILVA GD, et al. Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps. Frontiers in Neurology, 2020; 11.
SILVINATO A e FLORIANO I, et al. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Revista da Associação Médica Brasileira, 2022; 68(10): 1345–1357.
STRICKLAND JC, et al. Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy. Epilepsy & Behavior, 2021; 122: 108205.
STRZELCZYK A e SCHUBERT-BAST S. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies. CNS Drugs [Internet], 2021; 35(1): 61–83.
THIELE EA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England) [Internet], 2018; 391(10125): 1085–1096. Disponível em: https ://www.ncbi.nlm.nih.gov/pubmed/29395273. Acesso em: 31 maio 2024.
THIELE E, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia [Internet], 2019; 60(3): 419–428.
THIELE E, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia [Internet], 2019; 60(3): 419–428.
VARADKAR S. Cannabidiol for drop seizures in Lennox-Gastaut syndrome. The Lancet, 2018; 391(10125): 1006–1007.
VERROTTI A, et al. The pharmacological management of Lennox-Gastaut syndrome and critical literature review. Seizure [Internet], 2018; 63: 17–25.
WIJNEN, B, et al. Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2020; 38(10): 1043–1053.